Spherix Global Insights’ Quarterly Update on the Multiple Sclerosis Market Reveals a Unique Role for Genzyme’s Aubagio As the Only Oral Standard-Efficacy Therapy for First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Currently positioned by US neurologists to compete with Novartis’ siponimod in the later-line secondary progressive multiple sclerosis patient segment, EMD Serono’s Mavenclad could compete most successfully by strategically positioning the brand for first-line use in highly active relapsing multiple sclerosis patients, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., […]
Recent Progressive Forms of Multiple Sclerosis Chart Audit Provides Evidence That the Institute for Clinical and Economic Review’s Comparators of Interest for Novartis’ Siponimod Assessment May Not Be Relevant for the Not Active Secondary Progressive Multiple Sclerosis Segment
While Roche’s Ocrevus dominates the primary progressive multiple sclerosis segment, neurologists’ perceptions of the brand drive some to prescribe alternative monoclonal antibody therapies, according to a recently published independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 13, 2018 /PRNewswire/ — The Institute for Clinical and Economic Review (ICER) released their draft background and scope document on October […]
Uptake of Biogen’s Tecfidera and Increased Availability of Merck KGaA’s Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva’s Copaxone
Lack of access to Roche’s Ocrevus for primary progressive multiple sclerosis has stymied UK prescriber base growth and adoption over the past six months as much of Ocrevus’ early adoption in other EU countries came from first-line use among primary progressive multiple sclerosis patients due to the high unmet need and the agent’s first-to-market indication, […]
Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report
From: Multiple Sclerosis News Today By: Alice Melao
Genentech’s Ocrevus Positioning as an Appropriate First-Line Option in Relapsing Remitting Multiple Sclerosis Appears to Be Resonating With a Subset of U.S. Neurologists
Unaided awareness of EMD Serono’s Mavenclad (cladribine tablets) and Novartis’ siponimod increased compared to previous quarters, but neurologists appear split on how, or if, they will incorporate the newest agents into their multiple sclerosis armamentarium, according to a new report from Spherix Global Insights Download Report Overview EXTON, PA, September 19, 2018 (Newswire.com) – A […]
Ocrevus Predicted to Be a Billion-dollar Blockbuster
From: Multiple Sclerosis News Today By: Ed Tobias The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical industry, predicts that Ocrevus is “poised to blow past the $1B mark in the coming year. …” (read more).
Spherix Global Insights Announces Real World Audit Abstracts Accepted for Presentation at the 34th Congress of ECTRIMS In Berlin, Germany
The two abstracts compare U.S. neurologists’ self-reported perceptions with actual prescribing behavior to assess if the use of highly effective therapies as first-line treatment is increasing over time and what disease metrics and treatment expectations drive the selection of monoclonal antibody agents in patients recently switched to a new therapy EXTON, Pa., Aug. 7, 2018 […]
Recent Chart Audit of New Start Multiple Sclerosis Patients Confirms Dominance of the Oral Class, including Biogen’s Tecfidera, for First-Line Treatment But Finds Monoclonal Antibody Therapies, such as Genentech’s Ocrevus, Emerging as Legitimate Competitors
Teva’s Copaxone remains the brand share leader among new start patients year-over-year, although neurologists are beginning to write prescriptions for Mylan’s generic glatiramer acetate and Sandoz’s Glatopa independent of direct payer influence, according to a recently published independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., July 23, 2018 /PRNewswire/ — The oral […]
A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech’s Ocrevus Prescribing Patterns
The next opportunity for expansion of the treated patient pool for progressive forms of multiple sclerosis relies on potential launches of Novartis’ siponimod, MedDay Pharmaceuticals’ MD-1003, and AB Science’s masitinib, or label expansions of Genzyme’s Lemtrada or EMD Serono’s Mavenclad, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., June […]
Ocrevus Proves Mettle in Real-World PPMS – Adverse events from ongoing study in line with major trial results
From: MedPage Today By: Salynn Boyles, Contributing Writer, MedPAge Today NASHVILLE — Ocrelizumab (Ocrevus), the first and only FDA-approved disease-modifying therapy (DMT) to treat primary progressive multiple sclerosis (PPMS), has lived up to its hype, according to the CEO of the Consortium of Multiple Sclerosis Centers (CMSC). “Ocrelizumab has really changed the landscape for patients […]
